Endocrine Abstracts

Objective: To evaluate the baseline characteristics and their evolution three months after implantation of the Flash glucose monitoring System (Freestyle Libre), after financing by the Andalusian Health Service in patients under 18 years old with type 1 diabetes mellitus (DM1) in our hospital area.Material and Methods: A descriptive observational and retrospective study that includes patients with DM1 under 18 years old from the southern hospital area of...

The Spanish acromegaly registry (REA) is an online epidemiological database created in 1997 to collect clinical and biochemical data of patients with acromegaly followed in Spain.Aim: To study trends in acromegaly treatment over time in Spain.Methods: REA is an online database in which registered endocrinologists collect data from all acromegalic patients seen at their practices in Spain. In the last year the neuroendocrine group o...

Background and Objective: Congenital adrenal hyperplasia (CAH) is one of the most common diseases in pediatric endocrinology. Non-classical (NC-CAH) forms are characterized by milder enzyme dysfunction and manifests commonly in adolescence or adulthood. The most frequent form of NC-CAH occurs due to 21-hydroxylase deficiency which is caused by defects in the CYP21A2 gene. Our aim was to describe the most common 21-hydroxylase gene (CYP21A2) mutations in our geographical area i...

Background: Cross-sex hormone treatments are used to masculinize or feminize the bodies of female-to-male (FtM) or male-to-female (MtF) transsexuals, respectively. Redistribution of fat mass is expected to occur during the first 1–6 months in transgender males and in the first 3–12 months in transgender females.Objective: To examine the effects of cross-gender sex hormone therapy (CHT) on body composition in transsexual men and women.<p cla...

Background: Male-to-female transsexual persons use estrogens + antiandrogens to adapt their physical bodies to the female sex.Estrogens are powerful stimulators of synthesis and release of prolactin and serum prolactin levels are usually somewhat increased following estrogen treatment.Objective: To determine prolactin levels and to assess the risk of development of prolactinoma in male-to-female transgender subjects following cross-sex hormone therapy (C...

Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fractures although bone mineral density is increased. As such, there is a need for improved approaches to estimate fracture risk in such individuals. The Trabecular Bone Score (TBS) is a new technique to determine the trabecular bone microarchitecture.Objective: Our aim was to evaluate evaluate the usefulness of TBS in T2DM patients.Methods: We compared...

Background: The complex involvement of multiple metabolic defects in the pathogenesis of type 2 diabetes mellitus (T2DM) makes difficult the treatment in monotherapy, therefore, the use of different antidiabetic drugs with different and complementary mechanisms of action could result in better glycemic control with favorable metabolic changes.Objective: To determine the effectiveness and safety of the addition of a sodium-glucose co-transporter type 2 in...

Background: Cross-sex hormone therapy (CHT) is known to lead to alterations in cardiovascular risk factor(CVRF).Objective: To assess changes in lipid profile and other CVRF in transsexual subjects receiving CHT.Materials and methods: Retrospective longitudinal study. We evaluated individuals with gender identity disorder following CHT, assisted in the Gender Identity Unit from 2015 to 2017. Primary endpoint was lipid profile change...

Objectives: Assess the canagliflozin effect on the ABPI in patients without previous treatment with iSGLT-2 as a possible etiology of tissue hypoperfusion and a risk factor for amputations.Material and methods: Prospective observational study where we analyzed patients diagnosed of type 2 diabetes mellitus (DM2) with poor metabolic control and without prior treatment with iSGLT-2, which is initiated treatment with canagliflozin. Clinical, biochemical par...

Background: Pituitary adenomas (PA) and pheochromocytomas/paragangliomas (PCC/PGL) are the main components of MEN1 and MEN2, respectively. Although the presence of both tumors (3P association, 3PAs) in the same patient could be as a result of coincidence, at least in some cases, a common pathogenic mechanism has been involved. Recently has been confirmed that germline mutations in genes coding succinate dehydrogenase (SDH) play a role in pituitary tumorigenesis. Furthermore, M...